您当前的位置：
首页 >
文章列表页 >
Clinical characteristics and prognosis of severe immune checkpoint inhibitors-related liver injury in gastrointestinal malignancies
Article | 更新时间：2026-02-09

    • Clinical characteristics and prognosis of severe immune checkpoint inhibitors-related liver injury in gastrointestinal malignancies

    • “Experts from Zhongshan Hospital affiliated with Fudan University found that the incidence of immune checkpoint inhibitor related liver injury is 4.86%, and liver metastasis, combined TKI treatment, and high baseline GGT levels are risk factors. MELD score can effectively predict poor prognosis.”
    • China Oncology   Vol. 35, Issue 12, Pages: 1099-1107(2025)

    • DOI：10.19401/j.cnki.1007-3639.2025.12.002    

      CLC： R735

    • Received：29 August 2025，

      Revised：2025-12-03，

      Published：30 December 2025

    移动端阅览

  • MAO Tianxiao, JIANG Ying, WANG Chunhui, et al. Clinical characteristics and prognosis of severe immune checkpoint inhibitors-related liver injury in gastrointestinal malignancies[J]. China Oncology, 2025, 35(12): 1099-1107. DOI： 10.19401/j.cnki.1007-3639.2025.12.002.

  •  
  •  

0

Views

11

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

MDT consensus on immunotherapy for locally advanced head and neck squamous cell carcinoma (2025 edition)
Research progress of immune checkpoint inhibitors in the treatment of acral melanoma
Advances and future perspectives of neoadjuvant immunotherapy in colorectal cancer
Advances in immune checkpoint inhibitor therapy for breast cancer: research progress and future directions
Important clinical studies that changed the clinical practice of advanced breast cancer in 2024

Related Author

Chenping ZHANG
Chaosu HU
Ye GUO
Rui XU
Jiyong LIU
Cong RUAN
Jiajia QIAN
Qian LIU

Related Institution

Committee of Head and Neck Cancer, Chinese Society of Clinical Oncology
Department of Pharmacy, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University
Department of Pharmacy, Fudan University Shanghai Cancer Center Minhang Branch
Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
0